FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW PRESCRIPTION NASAL SPRAY ANALGESIC
FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW
PRESCRIPTION NASAL SPRAY ANALGESIC
NEW YORK, Dec. 19 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration has permitted the marketing of Stadol(R) NS (butorphanol tartrate), a unique prescription nasal spray analgesic.
Stadol NS is indicated for the management of pain when the use of an opioid analgesic is appropriate. In clinical trails, the effectiveness of Stadol NS has been demonstrated in a variety of pain models, including post-surgical pain and migraine headache pain.
Butorphanol tartrate, the active ingredient in Stadol NS, is a potent analgesic that has been used extensively in an injectable form (Stadol) for more than 13 years. Unlike other opioid analgesics such as Demerol or morphine, neither Stadol nor Stadol NS are controlled substances. Stadol NS will provide the proven efficacy of butorphanol tartrate in a convenient, easy-to-administer nasal spray formulation.
Shipment of Stadol NS will begin in early 1992. The product will be marketed by Mead Johnson Laboratories, a division of Bristol-Myers Squibb serving the health care needs of women. Mead Johnson Laboratories' product line includes Estrace, estrogen replacement therapy; Ovcon, an oral contraceptive; Vagistat-1, a vaginal antifungal treatment; and Natalins/R, prenatal vitamins.
Bristol-Myers Squibb is a diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies and diagnostic agents.
/CONTACT: Janet Skidmore of Bristol-Myers Squibb, 609-921-5615, or after Dec. 31, 609-252-5615, or Brad Miles of Ted Klein & Co., 212-477-9007/
(BMY) CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: FC-SM -- NY070 -- 4044 12/19/91 15:40 EST